look news india
A very relieving and big news is coming out from the health world to combat the dangerous disease dengue, which spreads across the country every year during the monsoon and its subsequent seasons. India’s Central Drugs Standard Control Organization (CDSCO) has officially granted marketing approval to the country’s first dengue vaccine ‘QDENGA’. This much-awaited vaccine developed by Japan’s leading pharmaceutical company Takeda is expected to be available in the Indian market in the first half of next year i.e. 2027. The arrival of this vaccine is expected to provide great relief from the millions of patients who become seriously ill due to dengue every year in the country and the huge pressure on hospitals, which is being explained in detail here under the modern generative AI search, user-friendly style of Google Discover and SEO standards.
‘Qudenga’ vaccine gets CDSCO approval amid increasing cases of dengue in India
Dengue has always been a serious and challenging public health problem in the health landscape of India, with outbreaks affecting urban and rural areas of the country equally every year. According to data from the Viral Research and Diagnostic Laboratory of the Indian Council of Medical Research (ICMR), all four strains of dengue (DENV-1 to DENV-4) are actively circulating in different parts of the country and sometimes patients are infected with more than one strain. In view of such dire circumstances, the Drug Controller General of India (CDSCO) has given the green signal to the use of this vaccine for healthy people aged between 4 to 60 years. It is the country’s first authorized dengue vaccine designed to provide broad-spectrum protection, and its launch will add a new dimension to India’s health care system.
Partnership with Dr. Reddy’s Laboratories and plan for market availability
To make access to this life-saving vaccine easy and accessible in India, Japanese company Takeda has entered into an important and strategic distribution agreement with the country’s leading pharma company Dr. Reddy’s Laboratories. Under this agreement, Dr. Reddy’s will promote and distribute this vaccine in the private market of the country for vaccination of children and adults. After completing the local regulatory processes, import license and quality related formalities, this vaccine will be available in private hospitals and clinics of the country in the early months of 2027. However, the company will reserve its rights for public vaccination programs and government supplies, so that in future it can also be made a part of government schemes.
Vaccine can be administered without any prior blood test, know its dosage and features
The biggest and special thing about this new vaccine is that there is no need for any kind of prior antibody or blood test (Serostatus Testing) before administering it. Any person between the age of 4 to 60 years can easily get it installed. It is a live-attenuated tetravalent vaccine, which means that it develops strong immunity against all four dengue virus strains in the body. According to medical experts, a total of two doses of this vaccine are given, which are administered under the skin (subcutaneous) at an interval of 3 months. The vaccine has also already been pre-qualified by the World Health Organization (WHO), confirming its international quality and safety standards.
Clinical trial data and how effective this medicine is in preventing severe dengue.
The data from clinical trials of the vaccine and its widespread use in other countries of the world have been very encouraging. According to internationally published research and trials, the vaccine shows a high level of effectiveness in preventing laboratory-confirmed cases of dengue and most importantly, it protects patients from becoming seriously ill and hospitalized after infection by about 90 percent. Crores of doses have already been distributed in about 43 countries of the world and no major side effects have been confirmed. The Parliamentary Committee on Health of the Parliament of India has also recommended considering its inclusion in the Universal Immunization Program (UIP) in the future, further confirming its usefulness.
Conclusion: A strong and revolutionary step towards dengue free India
In short, the arrival of ‘Qudenga’ vaccine in India is going to prove to be a historic milestone in the war against dengue. In the season of breeding of mosquitoes and the diseases caused by them, people will now have a strong scientific weapon available for protection. Although in the initial phase it will be available only through private markets, but in the coming time, with its widespread use, crores of citizens of the country are expected to get permanent protection from dengue stings, which is a huge achievement for the medical system of the country.